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Abstract 
This study compared the impact on carbohydrate metabolism of two combinedoral contraceptives (COCs). This 
open-label, single-center trial enrolled participants for a total of 15 cycles. Thirty-six women were randomized to 
receive either 20 µg ethinyl estradiol (EE) and 75 µg gestodene (GSD) or 20 µg ethinyl estradiol and 150 µg 
desogestrel (DSG) daily for 21 days out of 28. A glucose tolerance test was performed at baseline and cycles 6 
and 13. The area under the curve (AUC) for glucose increased in both study groups. The change was statistically 
significant (p = 0.036) for the 20 EE/75 GSD group at cycle 6 versus baseline. Fasting blood glucose at cycle 13 
was significantly (p < 0.01) higher for both treatment groups compared to baseline. No changes were found for 
fasting insulin and fasting C-peptide levels or for the AUCs of insulin or C-peptide. Both regimens were well 
tolerated. Gestodene and desogestrel in combination with 20-µg ethinyl estradiol induce similar changes in 
carbohydrate metabolism which are smaller than those described earlier for COCs containing higher estrogen 
doses or more androgenic progestins such as levonorgestrel. 
Keywords: Carbohydrate; Oral contraceptive; Estrogen; Progestogen; Glucose; Insulin 
 
1. INTRODUCTION 
Since the first reports indicating that combined oral contraceptives (COCs) can alter carbohydrate metabolism, 
this issue has acquired increased significance in the field of hormonal contraceptive development. The main 
concern is that a decreased glucose tolerance and chronic hyperinsulinism may elevate the risk of cardiovascular 
disease by enhancing atherogenesis. The use of oral contraceptives by healthy young women usually results in a 
slight reduction in glucose tolerance. Although changes in blood glucose and insulin levels are often statistically 
significant, they are usually within the normal range and most fluctuations reported do not appear to be clinically 
relevant [1,2]. 
The newer progestins, such as desogestrel or gestodene, exert only minor or no androgenic effects in comparison 
with the older progestins such as levonorgestrel. This may provide an advantage, as it has been suggested that 
progestins with androgenic properties exert a more pronounced adverse effect on glucose metabolism [3]. 
We have examined two COCs, both containing the same low dose of 20 µg ethinylestradiol but with either 
gestodene or desogestrel as their progestin compound. We were interested in the metabolic impact that these 
low-dose COCs may have on carbohydrate metabolism, and whether the two different progestin components 
have different effects. 
2. MATERIALS AND METHODS 
The study was conducted as an open-label, single-center trial with two independent randomly allocated treatment 
groups, who were enrolled for a total of 15 cycles. Ethics committee approval was obtained and all participants 
gave their written informed consent. 
Thirty-six women were randomized into two study groups. One group received the oral contraceptive 
combination consisting of 20 µg ethinyl estradiol with 150 µg desogestrel (20 EE/150 DSG; Mercilon®) and the 
other study group received 20 µg ethinyl estradiol with 75 µg gestodene (20 EE/75 GSD; Femoden 20®). After 
two initial cycles without treatment the pre-treatment values of the investigated parameters were recorded, that 
is, on Days 21 through 25 of the second pretreatment spontaneous cycle. The women then started pill intake on 
the first day of their withdrawal bleeding. In each of the 13 treatment cycles, the contraceptive pill was 
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administered for 21 days followed by a period of 7 days without medication. 
Methods for determination of blood glucose, plasma immunoreactive insulin and C-peptide have been described 
elsewhere [4]. 
The area under the concentration-time curve (AUC) responses during a glucose tolerance test (OGTT) was used 
to indicate deteriorations in glucose tolerance. Around Days 21 through 25 of the second cycle without 
medication, an OGTT was performed to obtain a baseline value before starting the administration of study oral 
contraceptives. This first OGTT was preceded by randomization to the designated study group. In the medication 
phase an OGTT was again performed during the period of last pill intake in Cycles 6 and 13. The OGTT was 
performed in the morning, after at least 12 h of fasting and after 3 days of unrestricted diet (at least 250-g 
carbohydrate in their diet on each of the 3 days preceding the test). Blood samples (fasting values) were drawn 
before the 75-g glucose load was given and 30, 60, 90, 120, 150, and 180 min thereafter. The plasma levels of 
glucose, insulin, and C-peptide were assayed in each sample. 
For glucose and insulin plasma levels, the AUC corrected for the value at 0 min was used as the variable value. 
The AUC was calculated using the following equation : AUC = 1/2 [(1/2 X0 + X30 + X60 + X90 + X120 + X150 + 
1/2 X180) - 6 X0] where X0-180 is the parameter measured in blood samples at the different time points. AUCs are 
then expressed in concentration × 1 h. Statistical evaluation of the AUCs and of the fasting levels of glucose, 
insulin, and C-peptide was performed using Student's t-test for paired observations, comparing the pretreatment 
values with those after 6 months and 13 months of treatment, respectively. Results are expressed as estimates of 
treatment effects with 95% confidence intervals. For the AUCs of glucose and insulin, both treatment groups 
were compared using an analysis of covariance (ANCOVA) using the AUC of the pretreatment cycle as 
covariate. The results are presented as p-values and adjusted means. Episodes of bleeding and any adverse events 
were recorded throughout the trial. 
Table 1: Mean values ± SD for the various parameters studied 
Parameter (units) Baseline After 6 cycles of treatment After 13 cycles of treatment 
20 EE ⁄ 75 GSD (n = 17)    
AUC glucose (g/L.h) 1.33 ± 0.77 1.81 ±0.91 1.69 ± 1.13 
AUC insulin (IU/ml.h) 187 ± 58 261 ± 129 228 ± 119 
AUC C-peptide (pmol/L.h) 2596 ± 981 2761 ± 739 2729 ± 790 
Fasting glucose (g/L) 0.71 ± 0.08 0.71 ± 0.08 0.78 ± 0.07 
Fasting insulin (IU/ml) 8.11 ± 5 8.0 ±3.5 7.0 ± 3.95 
Fasting C-peptide (pmol/L) 418 ± 100 431 ± 90 377 ± 64 
20 EE ⁄ 150 DSG (n = 14)    
AUC glucose (g/L.h) 1.33 ± 0.8 1.6 ±0.9 1.98 ± 2.1 
AUC insulin (IU/ml.h) 236 ± 81 275 ± 126 228 ± 110 
AUC C-peptide (pmol/L.h) 2828 ± 620 2672 ± 674 3223 ± 2152 
Fasting glucose (g/L) 0.68 ± 0.07 0.73 ± 0.1 0.76 ± 0.08 
Fasting insulin (µU/ml) 6.5 ± 3.5 7.2 ± 3.2 6.0 ± 3.8 
Fasting C-peptide (pmol/L) 404 ± 105 444 ± 77 381 ± 68 
3. RESULTS 
Thirty-six lean, healthy young women between 19 and 29 years of age were found to be eligible and were 
randomized for the study. In the pretreatment cycles, two women from the 20 EE/150 DSG group discontinued 
the trial. A further volunteer discontinued because she became pregnant during the second pretreatment cycle. 
During the course of the trial one woman in the 20 EE/150 DSG group and another one in the 20 EE/75 GSD 
group terminated the study for personal reasons. 
Both study COCs were well tolerated, with nine women in the 20 EE/75 GSD group and four women in the 20 
EE/150 DSG group reporting minor adverse events at least once during treatment. The most frequently reported 
symptoms were nausea (3 women) and acne (2 women). Bleeding which occurred outside the tablet-free interval 
was described as intracyclic bleeding, presenting either as scanty bleeding (spotting) or with the strength of a 
menstrual period (breakthrough bleeding). The incidence of spotting was high in the first treatment cycle in both 
groups and declined continuously afterwards. During the first treatment cycle, spotting was reported by 61% of 
women in the 20 EE/75 GSD group and by 41% in the 20 EE/150 DSG group. The range of slight intermenstrual 
bleeding varied from 0% to 23% for treatment cycles 2 to 6, and from 0% to 11% for treatment cycles 7 to 13. 
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One woman in the 20 EE/75 GSD group and three women in the 20 EE/150 DSG group reported an episode of 
heavier intermenstrual bleeding during study treatment. 
The mean AUCs for glucose and insulin as well as the fasting values for glucose, insulin and C-peptide are given 
in Table 1. During study treatment, the AUC for glucose increased relative to the pretreatment levels in both 
study groups. Statistical significance (p = 0.036) was reached for the change in 20 EE/75 GSD at the sixth 
treatment cycle versus baseline values (Table 2). Fasting blood glucose measured at treatment cycle 13 was 
significantly (p < 0.01) higher for both the 20 EE/75 GSD and 20 EE/150 DSG treatment groups when compared 
to the pretreatment levels. However, no significant changes were found for the AUCs of insulin or C-peptide, or 
for fasting insulin and fasting C-peptide levels. Comparison of the mean AUCs for glucose and insulin for both 
oral contraceptives, adjusted for differences in their pretreatment values, did not reveal any difference between 
the groups at 6 and 13 months of study treatment (Table 3). 
Table 2: Changes in experimental parameters from pretreatment (baseline) to 6 and 13 cycles after start of 
treatment 
Parameter 6 cycles treatment minus baseline 13 cycles treatment minus baseline 
 Estimate 95% confidence interval Estimate 95% confidence interval 
20 EE ⁄ 75 GSD     
AUC glucose 0.48 0.034 to 0.92* 0.36 -0.11 to 0.83 
AUC insulin 74 -5 to 153 41 -30 to 112 
AUC C-peptide 165 -549 to 879 76 -590 to 742 
Fasting glucose 0.005 -0.06 to 0.04 0.07 0.03 to 0.11** 
Fasting insulin -0.11 -2.6 to 2.3 -1.1 -3.1 to 0.92 
Fasting C-peptide 13 -39 to 65 -41 -104 to 21 
20 EE ⁄ 150 DSG     
AUC glucose 0.3 -0.2 to 0.8 0.68 -0.5 to 1.8 
AUC insulin 39 -24 to 103 -8 -77 to 60 
AUC C-peptide -156 -565 to 253 395 -972 to 1763 
Fasting glucose 0.05 -1.7 to 0.11 0.08 0.02 to 0.1*** 
Fasting insulin 0.7 -1.1 to 2.6 -0.5 -3.6 to 2.6 
Fasting C-peptide 40 -7.8 to 87 -23 -91 to 45 
p-values are for comparison between treatment value to baseline: * p = 0.036; ** p = 0.001, *** p = 0.008. 
Table 3: Comparison of both treatments: analysis of covariance (ANCOVA) for the area under the curve (AUC) 
for plasma glucose and insulin 
Parameter Treatment cycle Adjusted means  p-value
  20 EE ⁄ 75 GSD 20 EE ⁄ 150 DSG  
AUC insulin 6 268 268 0.9 
 13 231 225 0.9 
AUC glucose 6 1.81 1.65 0.6 
 13 1.69 1.98 0.6 
4. DISCUSSION 
It has previously been reported that past or current oral contraceptive usage does not influence the subsequent 
risk of diabetes [5]. Furthermore, there is no evidence that the changes in carbohydrate metabolism induced by 
combined oral contraceptives (COCs) have an adverse impact on microvascular disease or atherosclerotic 
processes in healthy women [6]. However, glucose intolerance and hyperinsulinism may be factors predisposing 
to arterial disease, particularly if additional risk factors such as obesity, family history of diabetes, age, and 
previous history of gestational diabetes are present [1,7]. 
In view of the fact that there is convincing evidence that hyperinsulinemia is a good predictor of myocardial 
infarction and other forms of arterial disease [8], it is desirable to use COCs which exert minimal impact on 
glucose tolerance. Although the OGTT is a somewhat static, single-point picture of the homeostasis of 
carbohydrate metabolism, and does not provide full information on the physiological process of insulin 
resistance induced by COCs in an individual woman, it may nevertheless help to evaluate the relative impact of 
different COCs on carbohydrate metabolism. 
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A number of studies have suggested that both the estrogen as well as the progestin component in hormonal 
contraception may be responsible for inducing insulin resistance. On the progestin side, it is interesting to note 
that with long-acting progestin-only injectable contraceptives, a significant increase in fasting blood glucose and 
2-h blood glucose after glucose load can be observed [9]. However, when using the more sophisticated glucose-
clamp technique, Shamma et al. [10] found evidence of a hyperinsulinemic response to glucose and increased 
insulin resistance in women using implants of levonorgestrel, a gonane progestin with a chemical structure 
related to DSG and GSD. Similar observations were made earlier with oral levonorgestrel during OGTTs [11]. 
The estrogen component of COCs is also implicated in lowering insulin sensitivity; among others authors, 
Kojima et al. [12] using an insulin tolerance test, showed that even low hormone doses, such as 20 µg (EE) 
administered alone, causes a reduction in insulin sensitivity. The effect of different combined OCs on overall 
glucose tolerance has accordingly been postulated to be a result of a combination of estrogen-induced insulin 
resistance and progestin-associated changes in insulin half-life or pancreatic secretion [13]. However, these 
pharmacodynamic effects cannot be easily ascribed to the estrogen or the progestogen component as the nature 
of these synthetic, alkylated, steroids may be different, their dose and the ratio estrogen/progestogen may also 
differ. 
Accordingly, high-dose COCs containing 50 µg ethinylestradiol and high progestin doses modulate glucose 
tolerance more markedly than lower dose preparations containing 35 µg ethinylestradiol or less [13]. When 
formulations containing the same progestin but in which the estrogen dose has been reduced from 50 to 20 µg 
are used, the degree of hyperinsulinemia is also reduced [14]. 
The effect on carbohydrate metabolism, measured by the OGTT, in the long-term use of a COC containing 30-
µg ethinylestradiol with 75 µg gestodene has been reported. Slight increases in glucose and insulin during 
treatment were observed, although these changes were not clinically relevant [15-17]. Reports on the effect on 
carbohydrate metabolism of monophasic preparations containing 20-µg ethinylestradiol and 150-µg desogestrel 
show the same pattern of slightly impaired glucose tolerance [16,18-20]. 
In this prospective randomized study, we compared 2 preparations containing the same dose of 20 µg 
ethinylestradiol but different 19-nortestosterone derivatives from levonorgestrel as progestins, both DSG and 
GSD being characterized by far less androgenic action than their parent progestin, levonorgestrel [3]. The 
glucose responses to OGTTs increased after administration of both preparations, and fasting glucose values were 
found to be higher after 13 months of treatment by 10 to 12% when compared to the pretreatment levels. 
However, all fasting values were within the clinically normal range. This is in line with earlier observations that 
the effect on fasting glucose levels are more accurately evaluated in trials lasting for at least 12 months as shorter 
durations often do not show an influence on fasting levels [3]. In the present study, the COCs investigated did 
not show any statistically detectable difference in the AUCs for glucose except at six months of use of EE + 
GSD versus baseline—a short-lived change. Once more, no abnormal value of blood glucose was recorded 
during the OGTTs. No statistical difference in the AUCs was detectable between both preparations used. This 
small decrease in glucose tolerance at 6 and 13 cycles of OC use is in good correlation with observations 
published earlier [21]. 
When insulin is cleft from its precursor proinsulin molecule, C-peptide is released into the portal vein in an 1:1 
ratio with insulin and can therefore be used as a marker for pancreatic insulin secretion. Changes in fasting 
insulin levels did not parallel the observed trend of a slight increase in glucose values seen during the study, and 
simultaneously no change in fasting levels of C-peptide was recorded during the use of both OCs, supporting the 
observation that fasting insulin concentrations remained unaffected. The fact that no hyperinsulinemia nor 
increased pancreatic insulin secretion was observed in either treatment group may indicate that the reduction in 
dose to 20 µg ethinylestradiol in combination with low dosages of progestins as well, triggers to a lesser degree 
peripheral insulin resistance. 
There was a very slight divergence, albeit not statistically significant in this study, in the insulin responses during 
OGTTs performed at 13 cycles of use of either OC : a slight decrease in AUC for insulin (-3.4%) versus baseline 
was recorded during use of EE + DSG and a moderate increase (+21%) during use of EE + GSD while 
pancreatic insulin response (depicted by the AUCs for C-peptide) did not change. Note that the apparent small 
increase in C-peptide AUC at 13 cycles of EE + DSG use is because of an outlier value. These observations of a 
somewhat increased response in circulating levels of insulin during use of the COC containing gestodene and 
decreased levels with desogestrel, while C-peptide concentrations do not change, may indicate a different impact 
of these steroids on liver function. Hypothetically, desogestrel may increase the hepatic clearance of insulin, a 
concept that has been previously suggested [13]. Regardless of the mechanism, both oral contraceptives in this 
study produced a smaller elevation in the plasma insulin response to glucose load than older preparations 
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particularly those containing levonorgestrel, reinforcing their positive safety profile. However, any predicted 
benefit in terms of reducing arterial disease will be difficult to demonstrate epidemiologically because of the 
rarity of the disease in young women [14]. 
We conclude that the progestins gestodene and desogestrel in combination with 20 µg ethinylestradiol induce 
similar changes in carbohydrate metabolism. These changes are small and are in good agreement with other 
studies concerning low-dose COCs containing the same progestins. It is interesting to note that previous studies 
have indicated that low-dose COCs containing new progestins such as DSG and GSD induced less decline in 
glucose tolerance and less insulin resistance than older COCs containing high dosages of older progestins such 
as levonorgestrel. These new OCs may therefore, provide related clinical advantages. 
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